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a b s t r a c t
Orphan drug clinical trials often are adversely affected by a lack of high quality treatment efﬁcacy data that can be
reliably compared across large patient cohorts derived from multiple governmental and country jurisdictions. It
is critical that these patient data be captured with limited corporate involvement. For some time, there have been
calls to develop collaborative, non-proprietary, patient-centric registries for post-market surveillance of aspects
related to orphan drug efﬁcacy. There is an urgent need for the development and sustainable deployment of these
‘independent’ registries that can capture comprehensive clinical, genetic and therapeutic information on patients
with rare diseases. We therefore extended an open-source registry platform, the Rare Disease Registry Framework (RDRF) to establish an Independent Rare Disease Registry (IRDR). We engaged with an established rare disease community for Gaucher disease to determine system requirements, methods of data capture, consent, and
reporting. A non-proprietary IRDR model is presented that can serve as autonomous data repository, but more
importantly ensures that the relevant data can be made available to appropriate stakeholders in a secure, timely
and efﬁcient manner to improve clinical decision-making and the lives of those with a rare disease.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).

1. Introduction
Orphan drugs are those that are developed to treat speciﬁc rare conditions. However, clinical trials for orphan drugs frequently are complicated by a paucity of available patients, heterogeneity in onset, clinical
course and genetic basis, and the scarcity of biomarkers to monitor response to therapy. Therapeutic dilemmas, such as the optimal age to
start therapy and dosage at various stages of therapy, therefore, are
often unresolved prior to a drug receiving marketing approval. Although
regulatory authorities request post-marketing data, this information is

Abbreviations: IRDR, Independent Rare Disease Registries; RDRF, Rare Disease Registry
Framework; GR, Gaucher registry; ICGG, International Collaborative Gaucher Group; DEs,
data elements; RML, Registry Mark-up Language; RML, Registry Mark-up Language; API,
application programming interface.
⁎ Corresponding author at: Centre for Comparative Genomics, Murdoch University,
Building 390, Murdoch 6150, Western Australia, Australia.
E-mail addresses: mbellgard@ccg.murdoch.edu.au (M.I. Bellgard),
knapier@ccg.murdoch.edu.au (K.R. Napier), abittles@ccg.murdoch.edu.au (A.H. Bittles),
Jeff.Szer@mh.org.au (J. Szer), sﬂetcher@ccg.murdoch.edu.au (S. Fletcher),
nzeps@ccg.murdoch.edu.au (N. Zeps), ahunter@ccg.murdoch.edu.au (A.A. Hunter),
Jack.Goldblatt@health.wa.gov.au (J. Goldblatt).

generally only related to safety and is generated by the sponsoring
drug company. Government incentives in the US, Australia and the EU
for orphan drug development have resulted in signiﬁcant advancement
in the treatments of rare conditions [1]. But, treatment effectiveness
across patient populations has become a contentious issue, with calls
for reform of the post-authorisation assessment of orphan drugs
through adaptive licensing processes [2]. One critical challenge is to acquire high quality treatment efﬁcacy data that can be compared reliably
across patient cohorts, and for rare conditions, typically derived across
governmental and country jurisdictions. Most importantly, these
patient data must be captured with limited corporate interference. As
a result, there has been a call to develop collaborative, industryindependent, patient-centric registries for post-market surveillance of
aspects related to drug efﬁcacy [2].
The development and sustainable deployment of non-proprietary
Independent Rare Disease Registries (IRDR) will serve as autonomous
data repositories for the collection of comprehensive clinical, genetic
and therapeutic information about patients with rare diseases. A resource of this nature has been identiﬁed as one of the “key outcomes
from stakeholder workshops at a symposium to inform the development of an Australian national plan for rare diseases” [3].
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In late 2014 the Wellcome Trust funded a Pathﬁnder Award to support and drive the establishment of an IRDR to serve as a model data
source for the collection of comprehensive clinical and genetic rare disease patient data, and thereby enable the development of target-speciﬁc
therapies and clinically differentiated products in the rare disease area.
This was to be achieved through collaboration with expert physicians,
patient organisations and registry development experts. In Australia,
there presently is no national strategy in place for people living with
rare diseases. It is envisaged that one element of a national rare disease
plan should include patient registries and the collection of relevant data
to beneﬁt all stakeholders involved in developing and using innovative
treatments. The creation of an IRDR will serve as a key instrument for
building and empowering rare disease patient communities. Such a registry would enable all rare disease stakeholders to achieve their different but complementary goals aimed at augmenting knowledge and
developing new therapeutic options for the future. As a priority, it was
proposed that the Gaucher registry (GR) would be developed and deployed as the ﬁrst IRDR.
Several existing drug registries collect data on the efﬁcacy, treatment
outcomes or toxicity of the three available enzyme replacement therapies; the International Collaborative Gaucher Group (ICGG) Gaucher
Registry (imiglucerase, supported by Genzyme, a Sanoﬁ Company) [4,
5], the Gaucher Disease Enzyme Replacement Therapy Registry
(taliglucerase alfa, supported by Pﬁzer) [20], and the Gaucher Observational Study (GOS, velaglucerase alfa, Shire Human Genetic Therapies).
Additionally, several national registries also operate in Spain [7,8],
Brazil [9], and France [6].
For Australian treated patients with Gaucher disease however, manual spreadsheets were kept for all patients, with only one industrymanaged registry available for some data entry (the ICGG Gaucher
Registry). This is not an ideal situation, especially since a single pharmaceutical company held the database, even though patients were subsequently treated with multiple drugs from different companies. The GR
described in this manuscript therefore seeks to include all Australian patients with Gaucher disease, irrespective of treatment status and independent of treatment type.
A component of the Pathﬁnder Award provided for the development
of an IRDR that would allow for an increase in knowledge on rare diseases
by pooling data from clinical and epidemiological research and real-life
drug use in communities. This is of particular importance in Australia, a
country that is sparsely populated and has a unique ethnic diversity
with 3% of the population Aboriginal and/or Torres Strait Islander [10],
and 28% ﬁrst generation migrants from over 200 countries [11]. A well implemented IRDR will increase opportunities not only for rare disease
treatments to be developed but also to enable independent postmarketing review of clinical efﬁcacy and safety. Consistent long-term collection of patient data will help create standards of care (including a minimum set of common data elements) that in turn can dramatically
improve patient outcomes and life expectancy, even in the absence of
new therapies. The IRDR would provide unique insight into the detail of
a country's health, social services planning and healthcare organisation.
A recent article by Hollak et al. [2] supported the call for independent
registries in Europe. The authors argue that ideally: registries are
disease-centred with data captured from pivotal, extended trials, natural histories and quality of life studies; they are not drug-centred; appropriate governance and patient data analysis is independent of
corporate inﬂuence; mandatory data capture for all doctors treating patients across Europe; and the launch of registries early in the development process of orphan drugs. Thus, there is alignment between the
motivation of the Wellcome Trust Award and the requirements outlined
in the article by Hollak et al. [2]
Here we deﬁne what we believe are core features of an IRDR and describe a registry framework that meets these needs, the Rare Disease
Registry Framework (RDRF). The RDRF has been tailored to Gaucher disease as the model rare disease, for which therapies are available from a
number of drug companies.
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2. Materials and methods (registry system overview)
The open source RDRF allows the efﬁcient deployment of web-based
registries that can be modiﬁed dynamically as registry requirements
evolve [12–16]. The RDRF employs a modular approach to registry design that empowers registry administrators to easily conﬁgure registries
without software developer effort, by allowing users to dynamically create all data elements (DEs), sections and forms that deﬁne a patient registry and to share DEs across registries. Registries are described in a
computer-readable text ﬁle, which allows a registry deﬁnition to be
imported/exported, versioned, and stored in a shared accessible environment. Multiple registries can also be deployed on a single site, and
patients can be deﬁned once, yet belong to multiple registries.
The RDRF allows multiple levels of access, through the dynamic conﬁguration of working groups, user groups, and permissions. User groups
may include clinical, genetic, curator and administration users, which
can be conﬁgured to have access to different forms and certain registry
functionality. Users are assigned access to working groups that may be a
clinic, state, or country jurisdiction. Users are only able to access the data
of patients who are assigned to the working groups for which they have
access permission, enabling efﬁcient collaboration for data entry across
jurisdictions (nationally, or internationally).
The RDRF not only facilitates the effective capture, storage, management and access of patient information, it is also interoperable with
other systems from which it can capture, import and store data, thereby
integrating patient details with clinical data and results [14]. The ability
to re-use DEs across multiple registries greatly assists in the standardization of data capture, allowing for effective data sharing for research
purposes.
The RDRF takes a conceptual approach to the design and development of patient registries to ensure access, security, privacy,
and to meet the need for harmonisation across multiple clinical
sites in a given country, or internationally. The RDRF also fulﬁlls
the key criteria required for sustainable registry development,
such as open-source, modular design, web-based, provision of an
application programming interface (API), and interoperability [13,
17–19].
We engaged with an established rare disease community for Gaucher disease to determine the system requirements, methods of data capture, consent, and reporting, and tailored the RDRF to meet these
requirements for the deployment of a Gaucher disease registry.

3. Results and discussion
Through detailed interactions with clinicians, patient advocates and
industry, we identiﬁed a signiﬁcant number of challenges that needed
to be addressed to establish IRDRs. These included: long-term sustainability once a registry is deployed; development and ongoing registry
enhancements; dynamic consent that can be modiﬁed once a registry
is deployed; standards for data elements, sections, and forms that can
be shared and which are not hard-coded into the registry; and data
that are not only time-stamped but also captured within a timestamped context.
The Rare Disease Registry Framework (RDRF) described in this manuscript has an extensive array of features to address these challenges, as
listed in Supplementary Table S1. The key functionality focus of the
RDRF was to develop a generic IRDR using Gaucher disease as the specific model, since there are already a number of therapies available for this
condition, with only one international registry open to Australian patients (the ICGG Gaucher Registry) operating within a single drug company (Genzyme, a Sanoﬁ Company). The framework for this registry has
been speciﬁcally designed for functionality and customisation to be
available at the end-user level rather than at the system development
level. A number of these key features are highlighted in the following
sections.
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Fig. 2. Conﬁgurable and customisable consent. a) Consent is now easily customised, with validation and applicability rules available. Time-stamping of when consent is provided in a
searchable table of consent sections. This assists Data Curators to identify patients who have not provided informed consent; b) Further information on individual consent questions
can be obtained by clicking on the patient name.

3.1. Context
A key requirement for a GR was to enable the capture of data in a
given context. We recognised a subtle but important distinction between time-stamping data entry in a data ﬁeld versus time-stamping
data entry according to an assessment date. We refer to the latter
form of time-stamping as a context. For Gaucher Disease the context is
‘Assessment date’. Without this functionality it would be difﬁcult for a
registry system to support post-authorisation assessment. The RDRF
can now support both forms of time-stamping for more general application to other diseases. Naturally, analytics and visualisation of patient

data can be conducted more meaningfully at a context level. Fig. 1 provides details of context.
3.2. Customisable consent
The RDRF has the ability to conﬁgure and customise consent (Fig. 2).
From extensive stakeholder engagement it became clear that consent
for a given disease registry is not static and should not be hard-coded
into the registry development. Consent requirements can change, and
individuals may choose to ‘modify’ their consent over time. When initially designing the consent model, in the RDRF an end-user

Fig. 1. Details of context. a) The ‘Patient Listing’ is where patients are viewed, and new patients are added by clicking the green ‘add patient’ button. The implementation of ‘context’ allows
new Assessments to be added for each patient, so all data entered into the registry may be viewed (previously only the latest data could be viewed); b) New Assessments are created as
needed. The Demographics and Consent Modules are deﬁned once when the patient is ﬁrst created, and the collection of Forms are created with each new Assessment; c) New patient
listing page for each individual patient showing all ‘Assessments’ and progress details.
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administering the patient registry is readily able to modify the consent
and can choose to deﬁne the required consent validation and application rules. For example, consent criteria must all be ‘checked’ or only a
selected ‘mandatory’ number agreed upon. Thus functionality/access
to other functions within a given registry will be determined according
to these rules. Having a digitised patient accessible and modiﬁable consent will facilitate data-sharing with other researchers to enhance collaborative investigations on rare disease cohorts.
3.3. Registry description language
The RDRF employs a description language [14] for all registry deﬁnitions. A Registry Mark-up Language (RML) can deﬁne a complete registry, a registry form, section, data element, permissible value and
permissible value group. Use of the RML means that a standard registry
deﬁnition can be shared. Similarly, deﬁnitions for forms, sections and
data elements can be shared. Note that sharing a registry RML is not
sharing the data contained within a given registry. The RML is located
in a shared online environment and can be categorised according to
any given ontology for both registries and data elements. For example,
NINDS deﬁne ‘common’ data elements and disease-speciﬁc data elements [21].
3.4. Security and multi-level access
From both application level and operational levels the RDRF supports an array of security options. From an application level perspective,
the RDRF is built on top of a technology framework that has long-term
support [22]. This framework itself provides distinct levels of built-in security including: Secure Socket Layer security encrypting all web trafﬁc
to and from the application; Cross-Site Request Forgery checking that is
a method of ensuring that falsiﬁcation of form submissions is near impossible; and login restrictions of all “views”. In addition, the RDRF itself
includes a fully conﬁgurable permissions layer (role-based security
model) that restricts the visibility of forms and ﬁelds to speciﬁed user
groups. Furthermore, the RDRF stores identifying patient contact/demographic data in a database that is totally distinct from any clinical/genetic data.
From an operational-level perspective, any deployment of a registry
will need to address operational security. This is security relating to the
environment in which the software runs, and cannot be addressed by
the software itself. The registry framework stores data in PostgreSQL
and MongoDB. The databases using these systems are encrypted,
which ensures that data are protected if the storage hardware is (for example) stolen, reused, or returned to the manufacturer to address a
fault. In this sense, storage includes all physical media that are used to
store registry data, including the volumes used by the database software, the volume on which the front end is installed, and any volumes
used for operating system “swap” space. Communication between the
web interface and the databases is encrypted to guard against conﬁdential data being intercepted “in transit”.
In terms of physical security, workstations including laptops used to
access the registry should require user authorisation, be subject to appropriate security policies, and have appropriate security software
installed. On any workstation on which reports may be downloaded
from the registry and stored, whole-disk encryption should be implemented on the device to guard against the risk of data exposure through
theft or accidental loss.
3.5. Reporting engine
The RDRF also supports a reporting engine. A user with administration privileges is able to customise the data contained within the registry to generate a report, which can be conﬁgured to be accessed by
certain user groups (Fig. 3). This report template can be saved and
reused as required. The reporting engine also enables various types of

reports to be generated, such as ‘current’ or ‘longitudinal’. While SQL
queries are used to select and aggregate demographic data as required,
simple check boxes for each DE contained in the registry (check for inclusion in the report) also enable ease of report construction as they
minimise the use of SQL queries.
3.6. Interoperability
A key feature for any registry is its ability to communicate with other
registries in a programmatic known as interoperability. The RDRF has
implemented an application programming interface (API) to achieve
this outcome. This API can be used to interrogate other systems, e.g.
other registries or allied systems, such as biobanks, via their APIs. Alternatively, if permissions are provided other systems can interrogate a
given registry implemented using the RDRF.
3.7. Sustainability
From our perspective, addressing an IRDR's sustainability is paramount. In this regard we consider four important dimensions to an
IRDR sustainability: utility, effectiveness, efﬁciency and agility. While
the ﬁrst three dimensions are broadly acknowledged in achieving sustainable solutions in general, we see the fourth dimension as critical
when considering registries. We have previously described patient registries as non-static entities. Registry requirements, their purpose, functionality, and access privileges evolve over time. For instance, consent,
either from a policy or individual's permission might change, new
data ﬁelds reporting new phenotypic measures or reﬁnement of
existing data elements must be catered for, or a registry might initially
be intended as a contact registry with functionality subsequently incorporated to convert it to a clinical registry [13].
A sustainable registry must be interoperable with other registries
and to allied systems, such as biobanks and clinical information management applications, be ﬁt for purpose, yet customisable for endusers with minimal requirements of software developers. This last
point in particular, is crucial in the facilitation of a sustainable registry
as it dramatically reduces registry maintenance costs without limiting
the ﬂexibility of the system to customise registries. The registry described in this paper has been developed to facilitate sustainability
and in this regard it meets each of the criteria listed above.
4. Conclusions
The RDRF has been developed with a focus on sustainability. A
sustainable registry must be able to interoperate efﬁciently with
other systems via an API. Such systems include other patient registries, biobanks and clinical information management systems. A
sustainable registry must also be open source, ﬁt for purpose,
customisable for end-users, and by end-users, with minimal involvement of software developers.
The RDRF has an extensive array of features. From our end-user
engagement we have recognised that a number of features that
might be considered bespoke by one rare disease community can,
in fact, be generalised so that these features can become available
to other rare disease communities. The advantage of the RDRF reported in this paper is that it will allow, and include, the incorporation of data directly reported by patients along with clinical
information reported by healthcare professionals. This will improve
the robustness, comprehensiveness and quality of the data entered.
Furthermore, modular additions, or adjustments to the ﬁelds, do
not require high level software input.
The IRDR project will serve as a key instrument for building and
empowering new and existing patient communities, augmenting
knowledge, patient care and developing new therapeutic strategies for
the future. It will facilitate a collaborative approach to the collection of
company independent post-marketing clinical outcome data that will
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Fig. 3. Reporting engine. a) Reports are customised through the reporting tool—access can be conﬁgured to certain user groups; b) Data Elements can be easily chosen for inclusion in the
report by clicking a check box; c) Once a report is conﬁgured, it may then be saved and viewed or downloaded—reports are generated at download with the latest registry data.

rationalise best practice utilisation of orphan drugs. The IRDR will thus
improve decision-making of health care providers at a national level, facilitating cost-effective programs for the subsidised management of
these extremely expensive drugs.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bcmd.2017.01.013.
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